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A B S T R A C T
Opportunistic screening based on the Pap smear has been undertaken in Croatia since 1953. However, cervical cancer
remains an important health problem in Croatia when compared to European countries with organised screening pro-
grammes. In Croatia, in addition to screening based on well established cytology, Human papillomavirus (HPV) testing
is widely used as secondary test as a triage to borderline cytology and as a follow-up after treatment of severe cervical
lesions. Many different approaches for HPV testing arose in Croatia over the last decade depending on the needs of each
medical institution involved. Presently, there is an urgent need for better networking between the laboratories, the imple-
mentation of quality assessment and the adaptation of a uniform system of referring to and reporting of HPV testing. In
conclusion, the best possible organisation for HPV testing would be essential for implementation of HPV testing as pri-
mary screening test in Croatia, an thus ultimately and hopefully, the more successful cervical cancer control.
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Background
Cervical cancer remains an important health problem
in Croatia where the incidence rate of 14.4/100,000 wo-
men recorded in 20041 is slightly lower than the average
world incidence (16.2/100,000 women-year) but much
higher than rates recorded in European countries with
organised screening programmes.
Cervical cancer is highly amenable to screening be-
cause it has a long pre-clinical phase with precursor le-
sions that can be identified by cervical cytology (Papa-
nicolaou or Pap smears) and that can be easily treated
using simple procedures if they are detected at an early
stage. Opportunistic screening based on the Pap smear
has been undertaken in Croatia since 1953 when the first
laboratory for gynaecological cytology was established in
Zagreb2. Since then, a network of more than 30 laborato-
ries has developed and now provides good coverage of a
large part of the target population. Opportunistic screen-
ing has produced a decrease in cervical cancer incidence
from 26/100,000 to 15/100,000 women-years between
1970 and 1990, although it remained almost stable there-
after1.
The European Code Against Cancer states that all
women from 25 years of age should participate in organ-
ised cervical screening programmes, the Council of the
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European Union has recommended that all Member Sta-
tes should implement organised cervical cancer screen-
ing programmes and the new European Guidelines now
state that cervical cancer screening should only be of-
fered within the context of an organised programme3,4.
In 2003, a panel of Croatian experts prepared a proposal
for the implementation of an organised screening pro-
gramme that was submitted to the Croatian Ministry of
Health and Social Welfare5. This proposal recommended
that the programme should start by offering conven-
tional Pap smears to all women from 25 to 64 years of age
(app. 1.2 million women) who should be screened annu-
ally for the first 3 years but with the screening interval
subsequently extended to 3 years for all women who have
had 3 consecutive normal Pap smears. The proposal also
recommended the implementation of liquid-based cytol-
ogy with the extension of the screening interval to 5
years and the addition of HPV testing for women over
the age of 305.
The implementation of an organised cervical screen-
ing programme in Croatia would be facilitated because
many of the necessary elements are already in place:
• high quality cytology; gynaecological cytology is a man-
datory sub-specialisation and cytotechnicians are re-
quired to participate in continuing education since 19672.
Also, gynaecological cytology is regularly reviewed and
updated with the last improvement being a refinement
of cytological classification to »Zagreb 2002« that was
adapted from »Zagreb 1990« and the »National Cancer
Institute Bethesda System 2001«6.
• a well developed network of quality controlled gyna-
ecologic cytology laboratories with extensive expertise
in gynaecologic cytology
• a nationwide network of gynaecologists that currently
offer screening to women,
• well established procedures for the diagnosis and treat-
ment of women with abnormal smears7,
• a tradition of expert colposcopy that has been in place
since 1992,
• a network of laboratories with extensive experience in
HPV testing for diagnostic purposes that has been in
place since 1995, and
• the computerisation of the health system that is now
in the process of being implemented.
However, opportunistic screening in Croatia does not
include the entire target population and this is reflected
in the mortality rate that has shown only a small de-
crease between 1970 and 2002 from 6/100,000 to 5/
100,000 women-years1 and the goal must be to reach the
very low rate of 2–3/100,000 women-year that has been
achieved by the Finnish screening programme8. As such,
there is now an urgent need for the implementation of a
properly organised, population-based screening pro-
gramme that would effectively combine all the new tech-
nologies in a rational approach that would maximise the
cost-effectiveness and equitably serve all the women of
Croatia. Very importantly, this programme would also
have to carefully consider the appropriate management
of women who have been vaccinated against HPV and
who would have a different risk profile from women who
had not been vaccinated9.
HPV Infections and Cervical Cancer
Persistent infection with HPV has now been con-
firmed as a necessary, although not sufficient cause of
cervical cancer10,11. There are more than 130 well charac-
terised HPV types, with approximately 40 types that can
infect the genital mucosa. These have been classified into
high-risk (hr) and low-risk (lr) HPV genotypes according
to their association with cervical cancer and its precursor
lesions; HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59,
68, 73 and 82 were classified as high-risk or carcinogenic
types, HPV 26, 53 and 66 as probably carcinogenic, while
HPV 6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81 and CP6108
were classified as low-risk types12.
The genital HPV types are primarily transmitted by
sexual contact and all women who have had a sexual rela-
tionship are at risk for both HPV infection and cervical
cancer. Host factors as well as behavioural and environ-
mental factors, may facilitate cancer development in
women with a persistent HPV infection and the risk of
cervical cancer increases with immunodeficiency, higher
parity, tobacco smoking, co-infection with other sexually
transmitted agents (human immunodeficiency virus HIV,
herpes simplex virus 2 HSV 2, Chlamydia trachomatis
and Neisseria gonorrhoeae) and long-term (>5 years) use
of oral contraceptives10. However, the association be-
tween hrHPVs and cervical cancer is the strongest ever
found for a human cancer with a relative risks for the de-
velopment of cervical cancer ranging from 50–500 de-
pending on the HPV genotypes, single or multiple HPV
infections and the amount of virus (virus load)10,11. Also,
cervical cancer will not occur in the absence of a persis-
tent infection with one of the oncogenic HPV types13.
Worldwide, HPV 16 is the most common hrHPV type
as it is found in 60% of cervical cancer cases, while HPV
type 18 is found in about 10%, types 45 and 31 in 4%
each, and types 33, 52 and 58 each in another 2%10. HPV
16 and 18 are also associated with about 25% of the low
grade cervical lesions (LSIL) and 50 to 60% of the high
grade cervical lesions (HSIL). HPV 6 and 11 are respon-
sible for about 10% of LSIL and about 90% of genital
warts that do not represent additional risk for cancer
developement10.
HPV infection is very common in young women, but
most infections are transient and resolve spontaneously
in 6 to 24 months. Only a very small percentage of HPV
infections will lead to precursor cervical lesions and only
those that persist long-term pose a risk for the develop-
ment of cancer. Cervical precursor lesions persist longer
and progress more quickly in women with hrHPV infec-
tions than in women with lrHPV infections or those
without HPV. Approximately 60% or more of cases of
mild dysplasia resolve spontaneously and only about 10%
progress to moderate or severe dysplasia within 2 to 4
years. In some cases, moderate or severe dysplasia may
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occur without an earlier detectable mild dysplasia stage.
Less than 50% of cases of severe dysplasia progress to in-
vasive carcinoma, with much lower rates seen in younger
women. Usually it takes 10 to 20 year for precursor le-
sions caused by hrHPV to progress to carcinoma and this
is what makes cervical cancer a relatively easily prevent-
able disease and provides the rationale for screening10.
Pap Smear and HPV Testing
Cervical cancer is rare before the age of 30 years.
Screening younger women detects many lesions that will
regress spontaneously and leads to considerable over-
treatment. Also, screening by Pap smear every three
years is nearly as effective as yearly screening. According
to the WHO recommendation if the resources are lim-
ited, screening every 5–10 years – or even just once be-
tween the ages of 35 and 45 years – will significantly re-
duce deaths from cervical cancer11. On the other hand,
negative HPV test virtually excludes any risk of having
significant prevalent cervical disease and provides the
same degree of protection over 5 years that the accepted
standard of a negative Pap smear provides over 2 years.
Therefore, it is likely that HPV testing could also provide
substantial cost savings for most European countries by
reducing the screening frequency with no increase in risk
for the women being screened14. However, HPV test-
ing-based screening should not begin before 30 years of
age.
Testing for HPV could be a useful cervical cancer
screening tool and its use has been proposed for primary
screening, triage of equivocal Pap smears and for the fol-
low-up of patients after treatment for severe cervical le-
sions. Women who test positive are at high risk of devel-
oping cervical precursor lesions and cancer and they
should be referred to more extensive diagnostic proce-
dures. About 15–30% of women with normal cytology
who are hrHPV positive will develop high-grade precan-
cerous lesions, cervical intraepithelial neoplasia (CIN)
grade 2 or 3 within 4 years of detecting the HPV in-
fection15. In contrast, women who test negative or are
lrHPV positive have almost no risk of developing cervical
precancer or cancer and it is thus justifiable to offer such
women less frequent screening.
HPV testing has been extensively evaluated and ma-
jor international reviews have concluded that it 1) is
more efficient than repeated cytology in the triage of am-
biguous cytological lesions, 2) is at least as efficient as cy-
tology as a primary screening test, and 3) is more effi-
cient than cytology as a test of follow-up for recurrence
after treatment of severe cervical lesions10. HPV testing
as primary screening, at this time, is recommended for
use only in pilot projects or other closely monitored set-
tings. Several large-scale randomised controlled trials for
evaluation of HPV testing for primary screening are at
the moment conducted in Europe9.
A comparative analysis of different studies on HPV
testing for primary screening showed that HPV testing
was substantially more sensitive in detecting CIN2+
than cytology (96.1% vs. 53.0%) but slightly less specific
(90.7% vs. 96.3%). The sensitivity of HPV testing was
uniformly high at all ages, whereas the sensitivity of cy-
tology was substantially better in women over the age of
50 than in younger women (79.3% vs. 59.6%), while the
specificity of both tests increased with age. These results
support the use of HPV testing as the sole primary
screening test, with cytology reserved for women who
test HPV positive16.
A good screening test should be accurate, reproduc-
ible, inexpensive, easy to perform and easy to follow-up,
acceptable and safe. HPV testing meets all of these crite-
ria, except for its high price, and this would probably de-
crease if the test is used on large-scale. At present, there
is only one HPV test approved by the United States Food
and Drug Administration (US FDA) and European Agen-
cy for the Evaluation of Medical Products (EMEA), the
Hybrid Capture 2 test (HC2; Digene Co.), which uses a
cocktail of 13 hrHPV types that are included within the
15 hrHPV types noted above.
Many other tests, commercial or in-house are poly-
merase chain reaction (PCR) based HPV tests, which
uses general (consensus) primers that recognise most hr-
and lrHPV types. The analysis of the PCR amplicon gen-
erated by consensus PCR by different methods (hybrid-
ization with specific probes, restriction fragment length
polymorphism analysis, and sequencing) enables deter-
mination of HPV types as well as direct type-specific
primer directed PCR. These methods of HPV genotyp-
ing, while sensitive and specific are too costly and cum-
bersome to incorporate into large-scale screening pro-
grammes. In the future, clinicians might benefit from
knowing the number and the identification of the specific
types present in order to follow for persistent infections
and/or to test for cure after therapy, and also to monitor
vaccinated women.
HPV Testing in Croatia
Laboratory network
In Croatia, several laboratories for molecular diagnos-
tics offer detection and genotyping of HPVs17–20. These
laboratories are located in Zagreb, Split, Rijeka and Osi-
jek, and belong to public or to private health care system;
only one laboratory is based in research setting. All labo-
ratories are equipped with special clean room to avoid
PCR amplicon contamination, specified equipment and
reagents required for a specific test. The work is per-
formed by highly trained technicians and supervised by
medical doctors, molecular biologists or medical bioche-
mists.
HPV testing methods
At present, there are several HPV testing systems
that are used in the established laboratory services in
Croatia. The first step in HPV testing is to collect an ade-
quate sample for HPV-DNA determination. HPV testing
can be performed using the same specimen collection me-
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dium used for cytological examination (Thin-Prep), or
dedicated collection medium specified by the manufac-
turer (Digene, Roche, and other). It should be noted that
sampling error and processing of the collected sample
could play an important role when using highly sensitive
molecular assays.
PCR was traditionally the first implemented method
for clinical use and is still used widely in most Croatian
laboratories17. HC2 method was the first commercial
method used in clinical laboratories but now, several
other commercial assays (PCR-based methods) are also
used: AMPLICOR HPV Test (Roche Co.) and TaKaRa
PCR Human Papillomavirus Typing Set (TAKARA Mirus
Bio Inc.). In addition, several laboratories offer in-house
consensus and type- specific PCR, HPV detection and
HPV genotyping by line blot assays (LiPA, Innogenetics;
LA HPV genotyping; Roche). Sequencing of PCR am-
plicon is used in only research setting.
Standardization and quality assessment
Standardization, quality assessment and quality con-
trol are important issues in any routine diagnostic test-
ing. They all serve to establish, maintain and guarantee a
high level of quality in the performance of a laboratory to
provide correct diagnoses that has a major influence on
the management of disease. In the past, substantial ef-
forts have been made by public and private organizations
to established and assure a high quality of diagnostic pro-
cedures. Standardization in protocols and methods, to-
gether with regular participation in internal and exter-
nal quality testing is essential for molecular diagnostic
laboratories21,22. The challenge for a laboratory that
wants to introduce this kind of testing is that it is very
demanding because of two major reasons: first, the mo-
lecular diagnostic tests are technically demanding and
require more expertise from the user compared to con-
ventional tests and secondly, because of the extreme sen-
sitivity of PCR and similar tests that can produce false
positive results created by contamination23. Scientific,
commercial or public institutions should provide panels
with negative and positive control specimens which will
be analysed on regular basis in diagnostic laboratories
participating in a quality control scheme. Data process-
ing and statistical analyses should be done by independ-
ent institutions that are responsible for supervising and
licensing procedures.
The HPV test should be performed in clinical labora-
tories with a supervision of specialist of microbiology, cy-
tology, pathology or a molecular biologist. Only tests that
have been validated and standardized tests for use in
clinical practice should be used and the laboratories
should have a validated license to perform the specific
test. Other, not clinically validated, HPV tests should be
done only for research purposes24. Interpretation of the
HPV test result should be done according to the standard
»cut-off« point recommended by the test manufacturer.
The referral order for HPV testing should include, be-
sides the general identification data, the date the sample
was taken, the date of birth, the stage of the menstrual
cycle, previous Pap smear findings and, if present, previ-
ous colposcopy, treatment and histological results.
The report of HPV test result should be composed of:
1) general patient data (name, date of birth), 2) referral
diagnosis (from the referral order: Pap test result, other
relevant colposcopic or histological results, 3) date of
sample taking, 4) referral physician and medical institu-
tion, 5) method of HPV testing, 6) interpretation of HPV
test result, and 7) optionally, recommendation of future
procedures or follow-up. However, the recommendation
should be given only by experts in the field of cervical le-
sions (gynecologic cytologists, pathologists and gynecolo-
gists) considering all clinical, cytological and pathological
data available about a particular patient, respecting the
accepted algorithms of follow-up or treatment of abnor-
mal cytology and histology7.
Conclusion
The higher sensitivity of HPV testing over cytology
offers a number of advantages, including, most impor-
tantly, the potential of reducing cervical cancer rates
while reducing the number of screens in a lifetime neces-
sary to achieve this goal. In Croatia, in addition to
screening based on well established cytology2, HPV test-
ing is widely used as secondary test as a triage to border-
line cytology and as a follow-up after treatment of severe
cervical lesions7. At present, screening is done only with
the conventional Pap test, and HPV testing therefore re-
quires an additional visit to gynaecologist which wastes
both time and money. Moreover, many different ap-
proaches for HPV testing arose in Croatia over the last
decade depending on the needs of each medical institu-
tion involved. Consequently, the implementation of HPV
testing in Croatia is still very heterogeneous and uncon-
trolled. So, there is an urgent need for better networking
between the laboratories, the implementation of quality
assessment and the adaptation of a uniform system of re-
ferring to and reporting of HPV testing. In conclusion,
the best possible organisation for HPV testing would be
essential for implementation of HPV testing as primary
screening test in Croatia, an thus ultimately and hope-
fully, the more successful cervical cancer control.
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HPV TESTIRANJE U PROBIRU RAKA VRATA MATERNICE U HRVATSKOJ – DANAS I SUTRA
S A @ E T A K
Oportunisti~ki probir temeljen na citolo{kom Papa-testu provodi se u Hrvatskoj od 1953. godine. Unato~ tome, u
usporedbi s Europskim dr`avama s organiziranim programima probira, rak vrata maternice u Hrvatskoj jo{ uvijek
predstavlja zna~ajni zdravstveni problem. UHrvatskoj, uz probir temeljen na priznatoj i dobro uhodanoj citologiji, HPV
testiranje sve se vi{e koristi kao sekundarni test razvrstavanja nakon grani~nog citolo{kog nalaza te kao kontrolni test
nakon lije~enja te`ih promjena vrata maternice. Tijekom posljednjih deset godina u Hrvatskoj se pojavljuju brojni raz-
li~iti pristupi HPV testiranju, ovisno o potrebama i stavovima pojedinih zdravstvenih ustanova koje ga primjenjuju.
Stoga se danas javlja neophodna potreba za boljom povezano{}u laboratorija, uspostavljanjem sustava kontrole kva-
litete i zauzimanjem ujedna~enog stava o indikacijama za HPV testiranje i na~inu izdavanja nalaza HPV testa. U zak-
lju~ku smatramo da }e najbolje mogu}e ure|en sustav HPV testiranja biti preduvjet za uvo|enje HPV testa u primarni
probir u Hrvatskoj, kao i uspje{niju borbu za suzbijanje raka vrata maternice.
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